Evaluating Abicipar for Safety and Treatment Effect in Patients With Neovascular Age-related Macular Degeneration (AMD)

Inclusion Criteria:

- Male or female patients, 50 years of age or older at the time of informed consent

- BCVA ≤ 78 and ≥ 24 letters (20/32 to 20/320 Snellen equivalents, respectively) at
screening and at baseline (Day 1, prior to treatment) visits in the study eye

- BCVA of 34 letters (Snellen equivalent 20/200) or better at baseline (Day 1, prior to
treatment) in the non-study eye

Exclusion Criteria:

- Active periocular, ocular, or intraocular infection at baseline (Day 1) (either eye)

- Previous or concurrent macular laser treatment ( study eye)

- Cataract or refractive surgery within 3 months prior to baseline ( study eye)